GLP-1 Microdosing: Evidence, Risks, Chart & Better Alternatives (2026) GLP-1 microdosing means using a dose well below the FDA-approved therapeutic range, typically 0.05 to 0.25 mg of semaglutide weekly versus the standard 1.7 to 2.4 mg
The SURMOUNT-5 head-to-head trial directly compared Zepbound to Wegovy, with results published in The New England Journal of Medicine: The addition of GIP receptor activation unlocks approximately 6% additional fat loss compared to GLP-1-only medications, while also helping preserve muscle mass better
Brand-name Wegovy lists near $1,349/month at retail, Eli Lillys direct Zepbound program starts around $299 for the lowest dose, and a growing list of telehealth platforms advertise compounded semaglutide between $189 and $249 per month
In the large prospective IMPROVE HF study, which enrolled 3994 patients, 28.6% of HFrEF patients showed an improvement of over 10% in EF at 24 months 10
The combination of security screening, variable cabin temperatures, baggage risks, and time zone changes creates unique challenges
For people who have found it difficult to lose weight despite dieting and exercising, GLP-1 medications can provide additional support